Between 2022 and 2025, Panpharma successfully managed a large-scale project involving the construction of new buildings and the installation of state-of-the-art production equipment dedicated to the aseptic filling of sterile powders. In June 2025, the development and qualification phases for both equipment and facilities were completed. Panpharma is now progressing with process validation for several …
News
Panpharma is modernizing its production by investing in a new vial filling line for injectable forms at its Trittau site in Germany.
August 2025 | Non classé
The launch of this new line is scheduled for late 2025, following inspections by the relevant authorities. Several qualification tests have already been carried out, and aseptic process simulation runs have been successfully completed. Training employees on the new filling line has been a top priority for Panpharma GmbH, with four weeks dedicated to training. …
Panpharma acquires Bayer’s marketing authorisation for injectable acetylsalicylic acid in Germany
August 2025 | Non classé
After obtaining European marketing authorisations (MA) for Sanofi’s injectable acetylsalicylic acid (formerly Kardegic® and Aspegic® injectables) a year earlier, Panpharma reached another major milestone at the end of 2024 by acquiring the German marketing authorisation for Bayer’s injectable acetylsalicylic acid (formerly Aspirin® I.V). This medicine, recognised for its major therapeutic value in cardiology, will thus …
Panpharma Is Committed to Reducing Its Environmental Impact
August 2025 | Non classé
Panpharma is fully committed to reducing its environmental footprint and is taking concrete action in line with its Corporate Social Responsibility (CSR) goals. The company has set a target to reduce its greenhouse gas emissions by 50% by 2030. As part of its continuous improvement efforts, Panpharma promotes a responsible purchasing policy and a sustainable …
Panpharma is investing more than 17 M€ in a new vial line
May 2022 | Non classé
Panpharma will invest more than 17 M € in a new vial line for injtectable forms in its Trittau plant in Germany which will more than double its production capacity. This modern and automated line will meet the latest regulatory standards (in particular the new EU GMP Annex 1) and will support the increase of …
Panpharma selected under the healthcare industry support plan.
May 2022 | Company, Innovation
Panpharma is the only producer of antibiotic in France with one of the world’s most comprehensive product ranges. Panpharma will be investing 25 million euros to modernise the production lines at its plant in Luitré, Brittany which will double its production capacity. This will meet the increased demand in France and for export, especially in …
Panpharma speaks at the Rencontres Santé Bretagne
November 2021 | Company
The ‘Rencontres Santé 2021 Bretagne’ conference, organised by Brittany’s regional healthcare agency, the Brittany region and Biotech Santé Bretagne, was held on 12 October 2021, covering the topics of challenges in training, innovation and production. Marie-Hélène Dick shared her experience by participating in a roundtable on healthcare products made in Brittany. More than ever, Brittany …
Panpharma belongs to the newly-created Franco-German club of healthcare companies
November 2021 | Company, Non classé
This club, named Tech & Fab for good, was launched on 7 October 2021 at the initiative of BPIfrance and in the presence of the minister responsible for industry, Ms Agnès Pannier-Runacher. It comprises 7 family-run, medium-sized French and German companies: Panpharma, BBraun, Thuasne, Septodont, Drager France, De Dietrich, Hartmann.The objective of this club is to …
Women in Industry prize 2021 awarded to our Chairwoman
November 2021 | Company
Marie Helene Dick, the chairwoman of Panpharma, received the honour of the Women in Industry 2021 trophy, awarded by [the magazine] ‘Usine nouvelle’, in the presence of Agnès Pannier-Runacher, secretary of state to the minister of the economy, on 28 September 2021.This prize recognises Panpharma for its history, its industrial expertise and its commitment to public …
A new Managing Director for the Panpharma Group
February 2021 | Non classé
Pierre Moysan became Chief Executive Officer of the Panpharma Group on the 1st of December 2020, after joining the group in mid-October. An engineer by training, Pierre began his career at L’Oréal, where he became director of a production unit. He soon joined the pharmaceutical industry and the GSK laboratory, initially in France and afterwards …